Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

Cassava Sciences announced that the phase 3 trial of its Alzheimer's drug, simufilam, did not meet its primary endpoints.

A little over three years later, this thing closed the day at $4.30, down 83% on the day. The cause? It’s Alzheimer’s drug Simufilam did not show a significant reduction in cognitive or functional ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...

Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...